{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:55:42Z","timestamp":1790834142477,"version":"4.1.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T00:00:00Z","timestamp":1670889600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T00:00:00Z","timestamp":1670889600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81974245"],"award-info":[{"award-number":["81974245"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Key Research and Development Program of Hubei Province","award":["YFXM2021000203"],"award-info":[{"award-number":["YFXM2021000203"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Cutaneous melanoma (CM, hereafter referred to as melanoma) is a highly malignant tumor that typically undergoes early metastasis. Pyroptosis, as a special programmed cell death process that releases inflammatory factors and has been widely studied in tumors, but its role in melanoma has not been fully elucidated. In this study, we examined the relationship between pyroptosis and the prognosis of melanoma through bioinformatic analysis of RNA-sequencing data. Our results demonstrated that pyroptosis is a protective factor associated with melanoma prognosis. A higher pyroptosis score was associated with a more favorable overall survival. We used weighted gene co-expression networks analysis (WGCNA) to establish an effective prognosis model based on 12 pyroptosis-related genes. We then validated it in two independent cohorts. Furthermore, a nomogram combining clinicopathological characteristics and a pyroptosis-related gene signature (PGS) score was designed to effectively evaluate the prognosis of melanoma. Additionally, we analyzed the potential roles of pyroptosis in the tumor immune microenvironment and drug response. Interestingly, we found that the elevated infiltration of multiple immune cells, such as CD4<jats:sup>+<\/jats:sup> T cells, CD8<jats:sup>+<\/jats:sup> T cells, dendritic cells, and M1 macrophages, may be associated with the occurrence of pyroptosis. Pyroptosis was also related to a better response of melanoma to interferon-\u03b1, paclitaxel, cisplatin and imatinib. Through Spearman correlation analysis of the 12 pyroptosis-related genes and 135 chemotherapeutic agents in the Genomics of Drug Sensitivity in Cancer database, we identified solute carrier family 31 member 2 (<jats:italic>SLC31A2<\/jats:italic>) and collagen type 4 alpha 5 chain (<jats:italic>COL4A5<\/jats:italic>) as being associated with resistance to most of these drugs. In conclusion, this PGS is an effective and novelty prognostic indicator in melanoma, and also has an association with the melanoma immune microenvironment and melanoma treatment decision-making.<\/jats:p>","DOI":"10.1038\/s41598-022-24879-y","type":"journal-article","created":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T18:03:00Z","timestamp":1670954580000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["The expression pattern of pyroptosis-related genes predicts the prognosis and drug response of melanoma"],"prefix":"10.1038","volume":"12","author":[{"given":"Bin","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Sha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinjin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lulu","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyun","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changzheng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,13]]},"reference":[{"key":"24879_CR1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.canlet.2014.11.001","volume":"357","author":"M Simoes","year":"2015","unstructured":"Simoes, M., Sousa, J. & Pais, A. Skin cancer and new treatment perspectives: A review. Cancer Lett. 357, 8\u201342 (2015).","journal-title":"Cancer Lett."},{"key":"24879_CR2","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1016\/j.jid.2016.01.035","volume":"136","author":"DC Whiteman","year":"2016","unstructured":"Whiteman, D. C., Green, A. C. & Olsen, C. M. The growing burden of invasive melanoma: Projections of incidence rates and numbers of new cases in six susceptible populations through 2031. J. Invest. Dermatol. 136, 1161\u20131171 (2016).","journal-title":"J. Invest. Dermatol."},{"key":"24879_CR3","first-page":"25","volume":"25","author":"C Garbe","year":"2022","unstructured":"Garbe, C. et al. European consensus-based interdisciplinary guideline for melanoma Part 1: Diagnostics: Update 2022. Eur. J. Cancer 25, 25 (2022).","journal-title":"Eur. J. Cancer"},{"key":"24879_CR4","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.abb.2014.06.030","volume":"563","author":"A Slominski","year":"2014","unstructured":"Slominski, A. et al. The role of melanogenesis in regulation of melanoma behavior: Melanogenesis leads to stimulation of Hif-1Alpha expression and Hif-dependent attendant pathways. Arch. Biochem. Biophys. 563, 79\u201393 (2014).","journal-title":"Arch. Biochem. Biophys."},{"key":"24879_CR5","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1002\/ijc.23664","volume":"123","author":"AA Brozyna","year":"2008","unstructured":"Brozyna, A. A., VanMiddlesworth, L. & Slominski, A. T. Inhibition of melanogenesis as a radiation sensitizer for melanoma therapy. Int. J. Cancer 123, 1448\u20131456 (2008).","journal-title":"Int. J. Cancer"},{"key":"24879_CR6","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1016\/j.humpath.2013.02.022","volume":"44","author":"AA Brozyna","year":"2013","unstructured":"Brozyna, A. A., Jozwicki, W., Carlson, J. A. & Slominski, A. T. Melanogenesis affects overall and disease-free survival in patients with stage III and IV melanoma. Hum. Pathol. 44, 2071\u20132074 (2013).","journal-title":"Hum. Pathol."},{"key":"24879_CR7","doi-asserted-by":"publisher","first-page":"17844","DOI":"10.18632\/oncotarget.7528","volume":"7","author":"AA Brozyna","year":"2016","unstructured":"Brozyna, A. A., Jozwicki, W., Roszkowski, K., Filipiak, J. & Slominski, A. T. Melanin content in melanoma metastases affects the outcome of radiotherapy. Oncotarget 7, 17844\u201317853 (2016).","journal-title":"Oncotarget"},{"key":"24879_CR8","doi-asserted-by":"publisher","first-page":"842496","DOI":"10.3389\/fonc.2022.842496","volume":"12","author":"RM Slominski","year":"2022","unstructured":"Slominski, R. M. et al. Melanoma, melanin, and melanogenesis: The Yin and Yang relationship. Front. Oncol. 12, 842496 (2022).","journal-title":"Front. Oncol."},{"key":"24879_CR9","doi-asserted-by":"publisher","first-page":"472","DOI":"10.3322\/caac.21409","volume":"67","author":"JE Gershenwald","year":"2017","unstructured":"Gershenwald, J. E. et al. Melanoma staging: Evidence-based changes in the American Joint Committee On Cancer Eighth Edition Cancer Staging Manual. CA Cancer J. Clin. 67, 472\u2013492 (2017).","journal-title":"CA Cancer J. Clin."},{"key":"24879_CR10","first-page":"20","volume":"20","author":"H Conor","year":"2019","unstructured":"Conor, H. & O\u2019Neill, C. R. S. Melanoma. J. Surg. Oncol. 20, 20 (2019).","journal-title":"J. Surg. Oncol."},{"key":"24879_CR11","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/nrclinonc.2017.43","volume":"14","author":"JJ Luke","year":"2017","unstructured":"Luke, J. J., Flaherty, K. T., Ribas, A. & Long, G. V. Targeted agents and immunotherapies: Optimizing outcomes in melanoma. Nat. Rev. Clin. Oncol. 14, 463\u2013482 (2017).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"24879_CR12","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s40257-022-00681-4","volume":"23","author":"F Aroldi","year":"2022","unstructured":"Aroldi, F. & Middleton, M. R. Long-term outcomes of immune checkpoint inhibition in metastatic melanoma. Am. J. Clin. Dermatol. 23, 331\u2013338 (2022).","journal-title":"Am. J. Clin. Dermatol."},{"key":"24879_CR13","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ctrv.2016.11.007","volume":"52","author":"JS O'Donnell","year":"2016","unstructured":"O\u2019Donnell, J. S., Long, G. V., Scolyer, R. A., Teng, M. W. & Smyth, M. Resistance to Pd1\/Pdl1 checkpoint inhibition. Cancer Treat. Rev. 52, 71\u201381 (2016).","journal-title":"Cancer Treat. Rev."},{"key":"24879_CR14","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.jaad.2020.11.047","volume":"84","author":"BS Allais","year":"2021","unstructured":"Allais, B. S. et al. Five-year survival in patients with nodular and superficial spreading melanomas in the US population. J. Am. Acad. Dermatol. 84, 1015\u20131022 (2021).","journal-title":"J. Am. Acad. Dermatol."},{"key":"24879_CR15","doi-asserted-by":"publisher","first-page":"2980","DOI":"10.3390\/ijms21082980","volume":"21","author":"ML Hartman","year":"2020","unstructured":"Hartman, M. L. Non-apoptotic cell death signaling pathways in melanoma. Int. J. Mol. Sci. 21, 2980 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"24879_CR16","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: The next generation. Cell 144, 646\u2013674 (2011).","journal-title":"Cell"},{"key":"24879_CR17","doi-asserted-by":"publisher","first-page":"847345","DOI":"10.3389\/fimmu.2022.847345","volume":"13","author":"J Liu","year":"2022","unstructured":"Liu, J. et al. Programmed cell death tunes tumor immunity. Front. Immunol. 13, 847345 (2022).","journal-title":"Front. Immunol."},{"key":"24879_CR18","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/s41418-018-0214-4","volume":"26","author":"MN Messmer","year":"2019","unstructured":"Messmer, M. N., Snyder, A. G. & Oberst, A. Comparing the effects of different cell death programs in tumor progression and immunotherapy. Cell Death Differ. 26, 115\u2013129 (2019).","journal-title":"Cell Death Differ."},{"key":"24879_CR19","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.molcel.2020.05.014","volume":"78","author":"A Strasser","year":"2020","unstructured":"Strasser, A. & Vaux, D. L. Cell death in the origin and treatment of cancer. Mol. Cell. 78, 1045\u20131054 (2020).","journal-title":"Mol. Cell."},{"issue":"Suppl","key":"24879_CR20","doi-asserted-by":"publisher","first-page":"S78","DOI":"10.1016\/j.semcancer.2015.03.001","volume":"35","author":"RM Mohammad","year":"2015","unstructured":"Mohammad, R. M. et al. Broad targeting of resistance to apoptosis in cancer. Semin. Cancer Biol. 35(Suppl), S78\u2013S103 (2015).","journal-title":"Semin. Cancer Biol."},{"key":"24879_CR21","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1002\/med.21398","volume":"36","author":"B Ke","year":"2016","unstructured":"Ke, B., Tian, M., Li, J., Liu, B. & He, G. Targeting programmed cell death using small-molecule compounds to improve potential cancer therapy. Med. Res. Rev. 36, 983\u20131035 (2016).","journal-title":"Med. Res. Rev."},{"key":"24879_CR22","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/imr.12534","volume":"277","author":"SM Man","year":"2017","unstructured":"Man, S. M., Karki, R. & Kanneganti, T. D. Molecular mechanisms and functions of pyroptosis, inflammatory caspases and inflammasomes in infectious diseases. Immunol. Rev. 277, 61\u201375 (2017).","journal-title":"Immunol. Rev."},{"key":"24879_CR23","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1146\/annurev-immunol-073119-095439","volume":"38","author":"S Kesavardhana","year":"2020","unstructured":"Kesavardhana, S., Malireddi, R. & Kanneganti, T. D. Caspases in cell death, inflammation, and pyroptosis. Annu. Rev. Immunol. 38, 567\u2013595 (2020).","journal-title":"Annu. Rev. Immunol."},{"key":"24879_CR24","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/nrmicro2070","volume":"7","author":"T Bergsbaken","year":"2009","unstructured":"Bergsbaken, T., Fink, S. L. & Cookson, B. T. Pyroptosis: Host cell death and inflammation. Nat. Rev. Microbiol. 7, 99\u2013109 (2009).","journal-title":"Nat. Rev. Microbiol."},{"key":"24879_CR25","doi-asserted-by":"publisher","first-page":"2647","DOI":"10.2147\/JIR.S308177","volume":"14","author":"N Ji","year":"2021","unstructured":"Ji, N. et al. Pyroptosis: A new regulating mechanism in cardiovascular disease. J. Inflamm. Res. 14, 2647\u20132666 (2021).","journal-title":"J. Inflamm. Res."},{"key":"24879_CR26","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.tins.2019.11.005","volume":"43","author":"BA McKenzie","year":"2020","unstructured":"McKenzie, B. A., Dixit, V. M. & Power, C. Fiery cell death: Pyroptosis in the central nervous system. Trends Neurosci. 43, 55\u201373 (2020).","journal-title":"Trends Neurosci."},{"key":"24879_CR27","doi-asserted-by":"publisher","first-page":"105408","DOI":"10.1016\/j.phrs.2020.105408","volume":"165","author":"J Wu","year":"2021","unstructured":"Wu, J., Sun, J. & Meng, X. Pyroptosis by caspase-11 inflammasome-gasdermin D pathway in autoimmune diseases. Pharmacol. Res. 165, 105408 (2021).","journal-title":"Pharmacol. Res."},{"key":"24879_CR28","doi-asserted-by":"publisher","first-page":"3620","DOI":"10.3390\/cancers13143620","volume":"13","author":"X Lu","year":"2021","unstructured":"Lu, X., Guo, T. & Zhang, X. Pyroptosis in cancer: Friend or foe?. Cancers 13, 3620 (2021).","journal-title":"Cancers"},{"key":"24879_CR29","doi-asserted-by":"publisher","first-page":"108270","DOI":"10.1016\/j.intimp.2021.108270","volume":"101","author":"S Qiu","year":"2021","unstructured":"Qiu, S., Hu, Y. & Dong, S. Pan-cancer analysis reveals the expression, genetic alteration and prognosis of pyroptosis key gene Gsdmd. Int. Immunopharmacol. 101, 108270 (2021).","journal-title":"Int. Immunopharmacol."},{"key":"24879_CR30","doi-asserted-by":"publisher","first-page":"3820","DOI":"10.1038\/onc.2017.26","volume":"36","author":"Z Zhai","year":"2017","unstructured":"Zhai, Z. et al. Nlrp1 promotes tumor growth by enhancing inflammasome activation and suppressing apoptosis in metastatic melanoma. Oncogene 36, 3820\u20133830 (2017).","journal-title":"Oncogene"},{"key":"24879_CR31","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/s41419-019-1883-8","volume":"10","author":"X Xia","year":"2019","unstructured":"Xia, X. et al. The role of pyroptosis in cancer: Pro-cancer or pro-\u201chost\u201d?. Cell Death Dis. 10, 613\u2013650 (2019).","journal-title":"Cell Death Dis."},{"issue":"Suppl 1","key":"24879_CR32","doi-asserted-by":"publisher","first-page":"S135","DOI":"10.1016\/j.ijsu.2016.06.014","volume":"33","author":"B Nardo","year":"2016","unstructured":"Nardo, B. et al. Liver resection for metastases from colorectal cancer in very elderly patients: New surgical horizons. Int. J. Surg. 33(Suppl 1), S135\u2013S141 (2016).","journal-title":"Int. J. Surg."},{"key":"24879_CR33","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1186\/s13046-020-01779-5","volume":"39","author":"S Sun","year":"2020","unstructured":"Sun, S. et al. A Novel circular Rna Circ-Lrig3 facilitates the malignant progression of hepatocellular carcinoma by modulating the Ezh2\/Stat3 signaling. J. Exp. Clin. Cancer Res. 39, 252 (2020).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"24879_CR34","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.tibs.2016.10.004","volume":"42","author":"J Shi","year":"2017","unstructured":"Shi, J., Gao, W. & Shao, F. Pyroptosis: Gasdermin-mediated programmed necrotic cell death. Trends Biochem. Sci. 42, 245\u2013254 (2017).","journal-title":"Trends Biochem. Sci."},{"key":"24879_CR35","doi-asserted-by":"publisher","first-page":"1873585","DOI":"10.1080\/2162402X.2021.1873585","volume":"10","author":"K de Jonge","year":"2021","unstructured":"de Jonge, K. et al. Inflammatory B cells correlate with failure to checkpoint blockade in melanoma patients. Oncoimmunology 10, 1873585 (2021).","journal-title":"Oncoimmunology"},{"key":"24879_CR36","doi-asserted-by":"publisher","first-page":"9559","DOI":"10.1038\/s41598-022-13391-y","volume":"12","author":"F Huang","year":"2022","unstructured":"Huang, F. et al. Next-generation sequencing in advanced Chinese melanoma reveals therapeutic targets and prognostic biomarkers for immunotherapy. Sci. Rep. 12, 9559 (2022).","journal-title":"Sci. Rep."},{"key":"24879_CR37","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/s41568-022-00442-9","volume":"22","author":"S Kalaora","year":"2022","unstructured":"Kalaora, S., Nagler, A., Wargo, J. A. & Samuels, Y. Mechanisms of immune activation and regulation: Lessons from melanoma. Nat. Rev. Cancer. 22, 195\u2013207 (2022).","journal-title":"Nat. Rev. Cancer."},{"key":"24879_CR38","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.semcancer.2019.08.002","volume":"59","author":"M Marzagalli","year":"2019","unstructured":"Marzagalli, M., Ebelt, N. D. & Manuel, E. R. Unraveling the crosstalk between melanoma and immune cells in the tumor microenvironment. Semin. Cancer Biol. 59, 236\u2013250 (2019).","journal-title":"Semin. Cancer Biol."},{"key":"24879_CR39","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1158\/1078-0432.CCR-17-2267","volume":"24","author":"TN Gide","year":"2018","unstructured":"Gide, T. N., Wilmott, J. S., Scolyer, R. A. & Long, G. V. Primary and acquired resistance to immune checkpoint inhibitors in metastatic melanoma. Clin. Cancer Res. 24, 1260\u20131270 (2018).","journal-title":"Clin. Cancer Res."},{"key":"24879_CR40","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1136\/jitc-2020-000832","volume":"9","author":"A Prokopi","year":"2021","unstructured":"Prokopi, A. et al. Skin dendritic cells in melanoma are key for successful checkpoint blockade therapy. J. Immunother. Cancer 9, 25 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"24879_CR41","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.ccell.2016.06.003","volume":"30","author":"EW Roberts","year":"2016","unstructured":"Roberts, E. W. et al. Critical role for Cd103(+)\/Cd141(+) dendritic cells bearing Ccr7 for tumor antigen trafficking and priming of T cell immunity in melanoma. Cancer Cell 30, 324\u2013336 (2016).","journal-title":"Cancer Cell"},{"key":"24879_CR42","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13045-020-00939-6","volume":"13","author":"Y Wang","year":"2020","unstructured":"Wang, Y. et al. Dendritic cell biology and its role in tumor immunotherapy. J. Hematol. Oncol. 13, 107 (2020).","journal-title":"J. Hematol. Oncol."},{"key":"24879_CR43","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s12935-020-01271-2","volume":"20","author":"B Huang","year":"2020","unstructured":"Huang, B., Han, W., Sheng, Z. F. & Shen, G. L. Identification of immune-related biomarkers associated with tumorigenesis and prognosis in cutaneous melanoma patients. Cancer Cell Int. 20, 195 (2020).","journal-title":"Cancer Cell Int."},{"key":"24879_CR44","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1038\/nm.2028","volume":"15","author":"F Ghiringhelli","year":"2009","unstructured":"Ghiringhelli, F. et al. Activation of the Nlrp3 inflammasome in dendritic cells induces Il-1Beta-dependent adaptive immunity against tumors. Nat. Med. 15, 1170\u20131178 (2009).","journal-title":"Nat. Med."},{"key":"24879_CR45","doi-asserted-by":"publisher","first-page":"108381","DOI":"10.1016\/j.celrep.2020.108381","volume":"33","author":"D Zhivaki","year":"2020","unstructured":"Zhivaki, D. et al. Inflammasomes within hyperactive murine dendritic cells stimulate long-lived T cell-mediated anti-tumor immunity. Cell Rep. 33, 108381 (2020).","journal-title":"Cell Rep."},{"key":"24879_CR46","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.jdermsci.2016.05.015","volume":"83","author":"T Fujimura","year":"2016","unstructured":"Fujimura, T., Kakizaki, A., Furudate, S., Kambayashi, Y. & Aiba, S. Tumor-associated macrophages in skin: How to treat their heterogeneity and plasticity. J. Dermatol. Sci. 83, 167\u2013173 (2016).","journal-title":"J. Dermatol. Sci."},{"key":"24879_CR47","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.it.2019.02.003","volume":"40","author":"P Pathria","year":"2019","unstructured":"Pathria, P., Louis, T. L. & Varner, J. A. Targeting tumor-associated macrophages in cancer. Trends Immunol. 40, 310\u2013327 (2019).","journal-title":"Trends Immunol."},{"key":"24879_CR48","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/s41586-020-2071-9","volume":"579","author":"Z Zhang","year":"2020","unstructured":"Zhang, Z. et al. Gasdermin E suppresses tumour growth by activating anti-tumour immunity. Nature (London) 579, 415\u2013420 (2020).","journal-title":"Nature (London)"},{"key":"24879_CR49","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1146\/annurev.immunol.24.021605.090733","volume":"24","author":"T Boon","year":"2006","unstructured":"Boon, T., Coulie, P. G., Van den Eynde, B. J. & van der Bruggen, P. Human T cell responses against melanoma. Annu. Rev. Immunol. 24, 175\u2013208 (2006).","journal-title":"Annu. Rev. Immunol."},{"key":"24879_CR50","doi-asserted-by":"publisher","first-page":"1786888","DOI":"10.1080\/2162402X.2020.1786888","volume":"9","author":"DCY Pico","year":"2020","unstructured":"Pico, D. C. Y. et al. Pd-1 checkpoint blockade in advanced melanoma patients: Nk cells, monocytic subsets and host Pd-L1 expression as predictive biomarker candidates. Oncoimmunology 9, 1786888 (2020).","journal-title":"Oncoimmunology"},{"key":"24879_CR51","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.3389\/fimmu.2020.02105","volume":"11","author":"F Maibach","year":"2020","unstructured":"Maibach, F., Sadozai, H., Seyed, J. S., Hunger, R. E. & Schenk, M. Tumor-infiltrating lymphocytes and their prognostic value in cutaneous melanoma. Front. Immunol. 11, 2105 (2020).","journal-title":"Front. Immunol."},{"key":"24879_CR52","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1158\/2159-8290.CD-20-0805","volume":"11","author":"SR Rosenbaum","year":"2021","unstructured":"Rosenbaum, S. R., Wilski, N. A. & Aplin, A. E. Fueling the fire: Inflammatory forms of cell death and implications for cancer immunotherapy. Cancer Discov. 11, 266\u2013281 (2021).","journal-title":"Cancer Discov."},{"key":"24879_CR53","doi-asserted-by":"publisher","first-page":"e2101840","DOI":"10.1002\/advs.202101840","volume":"8","author":"Y Xiao","year":"2021","unstructured":"Xiao, Y. et al. Microenvironment-responsive prodrug-induced pyroptosis boosts cancer immunotherapy. Adv. Sci. 8, e2101840 (2021).","journal-title":"Adv. Sci."},{"key":"24879_CR54","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s41586-020-2079-1","volume":"579","author":"Q Wang","year":"2020","unstructured":"Wang, Q. et al. A bioorthogonal system reveals antitumour immune function of pyroptosis. Nature 579, 421\u2013426 (2020).","journal-title":"Nature"},{"key":"24879_CR55","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s41577-018-0044-0","volume":"18","author":"J Borst","year":"2018","unstructured":"Borst, J., Ahrends, T., Babala, N., Melief, C. & Kastenmuller, W. Cd4(+) T cell help in cancer immunology and immunotherapy. Nat. Rev. Immunol. 18, 635\u2013647 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"24879_CR56","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/nri3191","volume":"12","author":"NP Restifo","year":"2012","unstructured":"Restifo, N. P., Dudley, M. E. & Rosenberg, S. A. Adoptive immunotherapy for cancer: Harnessing the T cell response. Nat. Rev. Immunol. 12, 269\u2013281 (2012).","journal-title":"Nat. Rev. Immunol."},{"key":"24879_CR57","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.humpath.2016.03.022","volume":"54","author":"K Garg","year":"2016","unstructured":"Garg, K. et al. Tumor-associated B cells in cutaneous primary melanoma and improved clinical outcome. Hum. Pathol. 54, 157\u2013164 (2016).","journal-title":"Hum. Pathol."},{"key":"24879_CR58","doi-asserted-by":"publisher","first-page":"756282","DOI":"10.3389\/fimmu.2021.756282","volume":"12","author":"R Mao","year":"2021","unstructured":"Mao, R., Yang, F., Zhang, T. & Li, J. Landscape and clinical significance of immune checkpoint in cutaneous melanoma. Front. Immunol. 12, 756282 (2021).","journal-title":"Front. Immunol."},{"key":"24879_CR59","doi-asserted-by":"publisher","first-page":"e542","DOI":"10.1016\/S1470-2045(16)30406-5","volume":"17","author":"GT Gibney","year":"2016","unstructured":"Gibney, G. T., Weiner, L. M. & Atkins, M. B. Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol. 17, e542\u2013e551 (2016).","journal-title":"Lancet Oncol."},{"key":"24879_CR60","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nrc.2016.36","volume":"16","author":"SL Topalian","year":"2016","unstructured":"Topalian, S. L., Taube, J. M., Anders, R. A. & Pardoll, D. M. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat. Rev. Cancer 16, 275\u2013287 (2016).","journal-title":"Nat. Rev. Cancer"},{"key":"24879_CR61","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1586\/erm.10.81","volume":"10","author":"M Neagu","year":"2010","unstructured":"Neagu, M., Constantin, C. & Tanase, C. Immune-related biomarkers for diagnosis\/prognosis and therapy monitoring of cutaneous melanoma. Expert Rev. Mol. Diagn. 10, 897\u2013919 (2010).","journal-title":"Expert Rev. Mol. Diagn."},{"key":"24879_CR62","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1158\/2159-8290.CD-19-0672","volume":"10","author":"DA Erkes","year":"2020","unstructured":"Erkes, D. A. et al. Mutant Braf and Mek inhibitors regulate the tumor immune microenvironment via pyroptosis. Cancer Discov. 10, 254\u2013269 (2020).","journal-title":"Cancer Discov."},{"key":"24879_CR63","doi-asserted-by":"crossref","unstructured":"Wang, D. et al. Increased Irf9-Stat2 signaling leads to adaptive resistance toward targeted therapy in melanoma by restraining gsdme-dependent pyroptosis. (2022).","DOI":"10.1016\/j.jid.2022.01.024"},{"key":"24879_CR64","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1038\/s41401-019-0222-z","volume":"40","author":"P Yu","year":"2019","unstructured":"Yu, P. et al. Eukaryotic elongation factor-2 kinase regulates the cross-talk between autophagy and pyroptosis in doxorubicin-treated human melanoma cells in vitro. Acta Pharmacol. Sin. 40, 1237\u20131244 (2019).","journal-title":"Acta Pharmacol. Sin."},{"key":"24879_CR65","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s13059-017-1349-1","volume":"18","author":"D Aran","year":"2017","unstructured":"Aran, D., Hu, Z. & Butte, A. J. Xcell: Digitally portraying the tissue cellular heterogeneity landscape. Genome Biol. 18, 220 (2017).","journal-title":"Genome Biol."},{"key":"24879_CR66","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41587-019-0114-2","volume":"37","author":"AM Newman","year":"2019","unstructured":"Newman, A. M. et al. Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat. Biotechnol. 37, 773\u2013782 (2019).","journal-title":"Nat. Biotechnol."},{"key":"24879_CR67","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s13059-016-1070-5","volume":"17","author":"E Becht","year":"2016","unstructured":"Becht, E. et al. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol. 17, 218 (2016).","journal-title":"Genome Biol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-24879-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-24879-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-24879-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T19:05:26Z","timestamp":1670958326000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-24879-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,13]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["24879"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-24879-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,13]]},"assertion":[{"value":"12 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21566"}}